New Markets are opening up. Technology is accelerating. It’s changing everything.
And creating fortunes in the process.
Dynamic Wealth Research exposes the biggest and most profitable changes for our readers.
Psychedelic drug development company Cybin will launch a phase two clinical trial on its sublingual formulation of psilocybin, the psychedelic compound found in “magic mushrooms”, for patients with Major Depressive Disorder later this year.
The company announced that the ethics board at the University of the West Indies Hospital in Jamaica granted approval this week.
Doug Drysdale, the company’s CEO, says the approval to start a clinical trial is a big step.
“I really think we have the opportunity to revolutionize how you treat mental illness,” says Drysdale, who worked in the pharmaceutical industry for 30 years before joining Cybin. “There’s nothing else out there today that could enable you to remove a person’s depressive symptoms for potentially months at a time.”
New drill results from Rua Gold's Reefton Goldfield Project include a high-grade gold intercept with visible gold in the core sample.
And creating fortunes in the process.
Dynamic Wealth Research exposes the biggest and most profitable changes for our readers.
